Oncology Xagena
Nivolumab ( Opdivo ) maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Cong ...
Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...
A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing cells with increased MET gene copy ...
The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...
Interim data from the phase 2 CheckMate -142 trial evaluating Nivolumab ( Opdivo ) alone or in combination with Ipilimumab ( Yervoy ) in patients with previously treated metastatic colorectal cancer, ...
The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer and have been treated with combination Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX)-base ...
Epacadostat is an oral, potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1 ), a tryptophan-catabolizing enzyme that induces immune tolerance by T-cell suppression. Preliminary phase ...
The baseline serum cytokine levels of Platinum pretreated patients with advanced squamous non-small cell lung cancer ( NSCLC ) altered the efficacy of immunotherapy with Nivolumab ( Opdivo ), a fully ...
Two-year overall survival data from two pivotal phase 3 studies evaluating Nivolumab ( Opdivo ) versus Docetaxel in previously treated metastatic non-small cell lung cancer ( NSCLC ) were announced. ...
Patients with metastatic urothelial carcinoma have few treatment options after failure of Platinum-based chemotherapy. In this trial, researchers have assessed treatment with Atezolizumab, an engineer ...
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs Lapatinib /( Tyverb; Tykerb ) and Trastuzumab ( Herceptin ) before surgery ...
The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of their distinct modes of action, different immunotherapies ha ...
Treatment with programmed death receptor-1 ( PD-1 ) antibodies is associated with high response rates in patients with advanced melanoma. Reliable markers for early response and outcome are still spar ...
Updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( MPDL3280A ) in people with locally advanced or metastatic urothelial carcinoma ...
Trials of salvage therapy for advanced urothelial carcinoma have required prior Platinum-based therapy. This practice requires scrutiny since non-Platinum-based first-line therapy may be offered to Ci ...
